Moxisylyte, also known as thymoxamine, is a drug used in urology for the treatment of erectile dysfunction.[1] It is an α1-adrenergic antagonist.[2] In the United Kingdom, Moxisylte is marketed as Opilon (Archimedes Pharma UK Ltd) and is used for the short-term treatment of primary Raynaud's syndrome. This is a condition where the fingers and toes become discoloured and is triggered by responses to cold, or emotional distress. Opilon tablets help by improving blood circulation to the extremities.[3][4]

Moxisylyte
Clinical data
Other namesThymoxamine
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 4-[2-(Dimethylamino)ethoxy]-5-isopropyl-2-methylphenyl acetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.000.186 Edit this at Wikidata
Chemical and physical data
FormulaC16H25NO3
Molar mass279.380 g·mol−1
3D model (JSmol)
  • CC1=CC(=C(C=C1OC(=O)C)C(C)C)OCCN(C)C
  • InChI=1S/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3
  • Key:VRYMTAVOXVTQEF-UHFFFAOYSA-N
  (verify)

References

edit
  1. ^ British National Formulary 69, Chapter2.6.4, page 142
  2. ^ Sakakibara R, Hattori T, Uchiyama T, et al. (March 2000). "Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte". J. Auton. Nerv. Syst. 79 (2–3): 191–5. doi:10.1016/S0165-1838(99)00105-8. PMID 10699651.
  3. ^ British National Formulary 70, page 205
  4. ^ "Opilon tablets - Patient Information Leaflet (PIL) - (eMC)". www.medicines.org.uk.